<DOC>
	<DOCNO>NCT01727700</DOCNO>
	<brief_summary>The goal current trial determine efficacy safety Once-daily aripiprazole reduce Total Tic Severity child adolescents Tourette 's Disorder .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Fixed-dose Once-daily Oral Aripiprazole Children Adolescents With Tourette 's Disorder</brief_title>
	<detailed_description>Tourette 's Disorder neuropsychiatric condition characterize appearance tic simple complex nature . A tic sudden , rapid , recurrent , non-rhythmic , stereotype motor movement vocalization . There limited number medication approve treatment Tourette 's Disorder . The goal current trial obtain efficacy , safety , tolerability data control condition Once-daily aripiprazole formulation child adolescents Tourette 's Disorder . The trial 8-week long double-blind treatment period pretreatment ( screening/washout phase ) , subject follow 1 month last treatment . The Once-daily tablet formulation evaluate trial represent daily dosage regimen intend administered child adolescent .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tic Disorders</mesh_term>
	<mesh_term>Tics</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>male female , 7 17 year old ( inclusive ) time sign consent meet DSMIVTR diagnostic criterion Tourette 's Disorder Presenting tic symptom cause impairment subject 's normal routine , include academic achievement , occupational functioning , social activity , and/or relationship Females childbearing potential must negative pregnancy test , must practice acceptable doublebarrier method contraception must pregnant lactate Written informed consent obtain legally acceptable representative &amp; informed assent Screening applicable trial center 's IRB/IEC The subject , designate guardian ( ) caregiver ( ) able comprehend satisfactorily comply protocol requirement , evaluate investigator Clinical presentation and/or history , consistent another neurologic condition may accompany abnormal movement History schizophrenia , bipolar disorder , psychotic disorder Subject receive psychostimulants treatment ADD/ADHD develop and/or exacerbation tic disorder initiation stimulant treatment Currently meet DSMIVTR criterion primary mood disorder Severe Obsessive Compulsive Disorder ( OCD ) Taken aripiprazole within 30 day Screening visit Received investigational agent clinical trial within 30 day prior Screening , enrol study 3112272 , 3112273 , 3112274 ; randomize clinical trial Oncedaily aripiprazole time History neuroleptic malignant syndrome Sexually active patient use 2 approved method contraception Females breastfeeding pregnant ( positive blood pregnancy test prior receive trial drug ) Risk commit suicide Body weight low 16 kg Taken neuroleptic antiparkinson drug &lt; 14 day prior randomization Requiring cognitive behavioral therapy ( CBT ) Tourette 's trial Subject meet DSMIVTR criterion significant psychoactive substance use disorder within past 3 month Positive drug screen Subject require medication allow per protocol Use CYP2D6 CYP3A4 inhibitor CYP3A4 inducer within 14 day prior dose duration trial Use herbal medication kind nutritional dietary supplement Tourette 's disorder within 7 day prior dose duration trial Inability swallow tablet tolerate oral medication Abnormal laboratory test result , vital sign ECG result</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Tourette Syndrome</keyword>
	<keyword>Basal Ganglia Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Tic Disorders</keyword>
	<keyword>Tics</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>